We are live on
!
Find out more
NC
Nexthera Capital Portfolio holdings
AUM
$120M
1-Year Est. Return
10.01%
This Fund
S&P 500
This Quarter
Est. Return
-10.3%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$171M
AUM Growth
+$7.86M
(+4.8%)
Cap. Flow
+$22.3M
Cap. Flow
% of AUM
13.05%
Top 10 Holdings %
Top 10 Hldgs %
64.38%
Holding
54
New
21
Increased
3
Reduced
8
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$14.3M |
| 2 |
CELG
Celgene Corp
CELG
|
+$13.6M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$12.2M |
| 4 |
SHPG
Shire pic
SHPG
|
+$11.2M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$9.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$14.9M |
| 2 |
Pfizer
PFE
|
+$10.8M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$6.02M |
| 4 |
Neurogene
NGNE
|
+$4.54M |
| 5 |
LCI
Lannett Company, Inc.
LCI
|
+$4.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SHPG
1
DELISTED
Shire pic
SHPG
| $22.1M | 12.98% |
130,000
+63,000
| +94% | +$11.2M |
|
|
2
Novartis
NVS
$285B
| $14.4M | 8.45% |
+220,968
| New | +$14.3M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $14.1M | 8.28% |
+122,000
| New | +$13.6M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
| $12.2M | 7.17% |
+100,000
| New | +$12.2M |
|
|
5
Pfizer
PFE
$141B
| $10.3M | 6.06% |
335,226
-354,144
| -51% | -$10.8M |
|
6
AstraZeneca
AZN
$255B
| $8.2M | 4.8% |
+150,000
| New | +$8.52M |
|
|
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $8.09M | 4.74% |
+500,000
| New | +$9.07M |
|
|
8
CALL
AstraZeneca
AZN
$255B
| $6.83M | 4% |
125,000
| – | – |
|
|
KITE
9
DELISTED
Kite Pharma, Inc.
KITE
| $6.73M | 3.94% |
+150,000
| New | +$7.36M |
|
|
TSRO
10
PUT
DELISTED
TESARO, Inc.
TSRO
| $6.72M | 3.94% |
+50,000
| New | +$6.31M |
|
11
Alnylam Pharmaceuticals
ALNY
$36.4B
| $6.18M | 3.62% |
+165,000
| New | +$6.91M |
|
12
Minerva Neurosciences
NERV
$204M
| $5.79M | 3.4% |
+61,620
| New | +$6.29M |
|
13
Neurocrine Biosciences
NBIX
$17.4B
| $4.64M | 2.72% |
+120,000
| New | +$5.43M |
|
|
XLRN
14
DELISTED
Acceleron Pharma
XLRN
| $4.54M | 2.66% |
178,000
-39,817
| -18% | -$1.26M |
|
15
Insmed
INSM
$23.2B
| $4.26M | 2.5% |
322,044
| – | – |
|
|
EIGR
16
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $3.07M | 1.8% |
8,787
-13
| -0.1% | -$4.76K |
|
17
Abeona Therapeutics
ABEO
$369M
| $2.76M | 1.62% |
22,743
+9,879
| +77% | +$1.55M |
|
|
ADMS
18
DELISTED
Adamas Pharmaceuticals
ADMS
| $2.56M | 1.5% |
151,670
-127,070
| -46% | -$1.97M |
|
|
KYNB
19
Kyntra Bio
KYNB
$28.5M
| $2.48M | 1.45% |
4,640
-467
| -9% | -$233K |
|
|
TRVN
20
DELISTED
Trevena, Inc.
TRVN
| $2.35M | 1.37% |
638
+160
| +33% | +$572K |
|
|
TVRD
21
Tvardi Therapeutics
TVRD
$27.5M
| $2.32M | 1.36% |
+6,944
| New | +$2.23M |
|
|
LUMO
22
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $2.06M | 1.21% |
+22,222
| New | +$2.5M |
|
23
Ascendis Pharma A/S
ASND
$16.5B
| $2.02M | 1.19% |
100,000
-46,200
| -32% | -$923K |
|
|
ZGNX
24
DELISTED
Zogenix, Inc.
ZGNX
| $1.82M | 1.07% |
150,000
-110,000
| -42% | -$1.21M |
|
|
CNCE
25
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $1.73M | 1.01% |
167,866
| – | – |
|
Similar funds
KAM
VCP
PFC
FCA
TA
EBIM
BCM
ACP
Nexthera Capital's Q4 2016 Portfolio in Review
As of Q4 2016, Nexthera Capital held 54 positions worth $171M, up 4.8% from $163M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Nexthera Capital deployed $22.3M of net new capital in Q4 2016, opening 21 new positions and adding to 3 existing holdings. Its largest new stake was Novartis: 220,968 shares worth $14.4M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 70% a quarter earlier.
On the sell side, the largest reduction was Pfizer, an estimated $10.8M trimmed.
- Nexthera Capital's largest Q4 2016 buy was Novartis: 220,968 shares worth $14.4M.
- Nexthera Capital added most to Shire pic in Q4 2016, an estimated $11.2M increase.
- Nexthera Capital's biggest Q4 2016 reduction was Pfizer, cutting an estimated $10.8M.
- Nexthera Capital fully exited GSK in Q4 2016, selling an estimated $14.9M.
- Nexthera Capital's ten largest holdings make up 64% of its $171M portfolio in Q4 2016.
- Nexthera Capital opened 21 new positions and closed 15 in Q4 2016.
- Nexthera Capital's portfolio value rose 4.8% quarter-over-quarter to $171M.
Based on Nexthera Capital's 13F filing for Q4 2016, filed 14 Feb 2017.